A Specialized Intermediate Behind Next-Generation Cystic Fibrosis Therapy

The development of modern medicines increasingly depends on highly specialized pharmaceutical intermediates. Some intermediates are not designed to have pharmacological activity themselves, but their molecular architecture can be essential for constructing a sophisticated active pharmaceutical ingredient (API).

3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole, CAS No. 2229861-93-0, is one such specialized compound associated with the synthesis of Vanzacaftor, a CFTR modulator developed by Vertex Pharmaceuticals.

PubChem identifies CAS 2229861-93-0 as 3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole, with molecular formula C₁₂H₁₆N₂O and molecular weight 204.27 g/mol.

Its relevance is closely connected to the development of next-generation treatments for cystic fibrosis (CF).

1. Product Identity at a Glance

The fundamental information for this pharmaceutical intermediate is:

The compound is also indexed under alternative structural names, including 3-(2-(dispiro[2.0.2.1]heptan-7-yl)ethoxy)-1H-pyrazole. PubChem lists the compound’s IUPAC name as 5-(2-dispiro[2.0.2⁴.1³]heptan-7-ylethoxy)-1H-pyrazole.

For procurement and regulatory documentation, customers should always identify the material using the CAS number, agreed chemical name, molecular formula, and supplier specification rather than relying on a shortened product name alone.

2. Why the Dispiro Structure Matters

At first glance, the name 3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole appears highly technical.

The complexity comes primarily from the dispiroheptane structural motif attached through an ethoxy linker to a pyrazole ring.

This type of three-dimensional architecture is increasingly important in medicinal chemistry.

Compared with highly planar aromatic structures, saturated and three-dimensional fragments can help medicinal chemists explore:

• · Molecular shape
• · Steric effects
• · Conformational behavior
• · Hydrophobic interactions
• · Spatial orientation of functional groups

The dispiro-containing structure therefore represents more than simply another substituted pyrazole.

It is a three-dimensional molecular building block that contributes structural complexity to downstream pharmaceutical synthesis.

3. The Connection with Vanzacaftor

The commercial importance of this intermediate comes from its relationship with Vanzacaftor (VX-121).

Vanzacaftor is a CFTR corrector developed by Vertex Pharmaceuticals. It became part of the once-daily triple combination vanzacaftor/tezacaftor/deutivacaftor, marketed as ALYFTREK™.

The Cystic Fibrosis Foundation identifies ALYFTREK as one of the approved CFTR modulator therapies and describes vanzacaftor and tezacaftor as correctors that help CFTR proteins achieve a more functional form and reach the cell surface.

Vertex announced U.S. FDA approval of ALYFTREK in December 2024 for eligible patients aged 6 years and older with responsive CFTR mutations.

The European Commission subsequently approved ALYFTREK in July 2025 for people with cystic fibrosis aged 6 years and older with at least one non-class I CFTR mutation.

This regulatory progress has increased the importance of reliable supply chains for the specialized intermediates used in the manufacture of its active components.

4. What Is the Role of a Vanzacaftor Intermediate?

A pharmaceutical intermediate is a compound used during the multi-step synthesis of an API.

It does not necessarily appear in the final pharmaceutical product.

Instead, it provides a controlled molecular framework from which subsequent chemical transformations can construct the final active ingredient.

For CAS 2229861-93-0, the combination of a pyrazole ring and dispiroheptane-containing side chain provides a structurally defined building block associated with Vanzacaftor synthesis.

This makes the product particularly relevant to:

• · Pharmaceutical R&D
• · API intermediate development
• · Process chemistry
• · Route optimization
• · Commercial pharmaceutical supply chains

Importantly, describing CAS 2229861-93-0 as a Vanzacaftor intermediate does not mean that the compound itself is the active CFTR modulator.

It is a synthetic intermediate used in the construction of the pharmaceutical molecule.

This distinction is important when communicating technical information to pharmaceutical customers.

5. Vanzacaftor and the Evolution of CFTR Modulator Therapy

Cystic fibrosis is a genetic disease associated with mutations in the CFTR gene.

The CFTR protein plays an important role in regulating chloride and water movement across epithelial cells.

When CFTR function is impaired, abnormal ion and water transport contributes to the characteristic manifestations of cystic fibrosis.

CFTR modulators approach the disease at the molecular level.

The Cystic Fibrosis Foundation explains that CFTR modulators are designed to correct defects in the CFTR protein, with different medicines targeting different aspects of CFTR dysfunction.

Vanzacaftor belongs to the corrector class.

It is designed to improve CFTR protein processing and trafficking, while the triple combination with tezacaftor and deutivacaftor provides complementary mechanisms.

This makes Vanzacaftor an important component of the continued evolution of CFTR modulator therapy.

6. From Specialty Intermediate to Pharmaceutical Supply Chain

The development of a pharmaceutical API involves considerably more than identifying a viable synthetic reaction.

A commercially useful intermediate must also meet requirements for:

Identity → Purity → Batch consistency → Documentation → Supply reliability

For a structurally specialized intermediate such as CAS 2229861-93-0, consistency becomes particularly important.

A change in:

• · Chemical purity
• · Residual impurities
• · Water content
• · Isomeric profile
• · Trace contaminants

can potentially influence downstream reactions and purification.

Consequently, pharmaceutical customers typically require detailed technical documentation before approving an intermediate supplier.

7. What Buyers Should Evaluate for CAS 2229861-93-0

When sourcing 3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole, buyers should consider several factors.

Chemical Identity

Confirm:

CAS No. 2229861-93-0

Molecular Formula: C₁₂H₁₆N₂O

Molecular Weight: 204.27 g/mol

Purity

The required assay should be clearly defined according to the customer’s application and specification.

Analytical Documentation

A professional supplier should be able to provide appropriate batch documentation, such as:

• · COA
• · Specification
• · Analytical data
• · Batch information
• · SDS where applicable

Batch Consistency

For API development and manufacturing, reproducibility between batches is critical.

Supply Capability

Customers should also evaluate whether the supplier can support the required quantity and maintain continuity as development progresses toward commercial production.

8. Why Specialized Intermediate Suppliers Matter

Products such as CAS 2229861-93-0 are different from commodity chemicals.

The value is not simply determined by the molecular formula or catalog availability.

A pharmaceutical customer may require:

• · Reliable synthesis
• · Controlled impurity profiles
• · Reproducible analytical results
• · Flexible batch sizes
• · Technical documentation
• · Long-term supply planning

For this reason, selecting a pharmaceutical intermediate supplier should involve both technical qualification and supply-chain evaluation.

A supplier capable of supporting customers from laboratory development through larger-scale procurement can provide greater value than a supplier offering only spot availability.

9. SHLZ Pharma and Vanzacaftor Intermediate Supply

SHLZ Pharma supplies 3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole CAS No. 2229861-93-0 for customers involved in pharmaceutical and advanced chemical development.

The product is positioned as a Vanzacaftor intermediate, supporting customers looking for specialized building blocks associated with next-generation CFTR modulator chemistry.

For international pharmaceutical customers, SHLZ Pharma focuses on the key elements required for intermediate sourcing:

• · Accurate product identification
• · Defined quality specifications
• · Batch documentation
• · Professional packaging
• · Reliable communication
• · Stable supply capability

The objective is to provide a dependable source for specialized pharmaceutical intermediates rather than treating these materials as ordinary catalog chemicals.

10. Frequently Asked Questions

What is CAS 2229861-93-0?

CAS 2229861-93-0 is 3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole, a specialized pyrazole-containing pharmaceutical intermediate.

What is the molecular formula?

The molecular formula is C₁₂H₁₆N₂O.

What is its molecular weight?

Its molecular weight is 204.27 g/mol.

What is CAS 2229861-93-0 used for?

It is used as a Vanzacaftor intermediate, associated with the synthesis of Vanzacaftor, a CFTR corrector.

What is Vanzacaftor?

Vanzacaftor, also known as VX-121, is a CFTR corrector developed by Vertex Pharmaceuticals and used as part of the vanzacaftor/tezacaftor/deutivacaftor combination.

What is ALYFTREK?

ALYFTREK is the brand name for the once-daily combination of vanzacaftor, tezacaftor, and deutivacaftor used for the treatment of cystic fibrosis in eligible patients.

Conclusion

3-(2-Dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazole CAS 2229861-93-0 is a specialized pharmaceutical intermediate distinguished by its combination of a pyrazole ring and a three-dimensional dispiroheptane-containing structure.

With a molecular formula of C₁₂H₁₆N₂O and molecular weight of 204.27 g/mol, the compound is associated with the synthesis of Vanzacaftor, a next-generation CFTR corrector.

The importance of this intermediate is closely linked to the growing role of CFTR modulator therapy in cystic fibrosis. Vanzacaftor is now part of the once-daily ALYFTREK triple combination with tezacaftor and deutivacaftor, which has received regulatory approvals in major markets.

For pharmaceutical companies sourcing this type of advanced intermediate, chemical identity, purity, batch consistency, analytical documentation and supply reliability are essential considerations.

SHLZ Pharma provides CAS 2229861-93-0 Vanzacaftor Intermediate for customers seeking a reliable source of specialized pharmaceutical building blocks for API development and manufacturing.